Scroll

acalabrutinib 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definition	Drug id	CAS RN
tyrosine kinase inhibitors	5260	1420477-60-6

Description:

Molecule	Description
Molfile Inchi Smiles Synonyms: acalabrutinib ACP-196 calquence	Acalabrutinib is a small-molecule inhibitor of BTK. Acalabrutinib and its active metabolite, ACP-5862, form a covalent bond with a cysteine residue in the BTK active site, leading to inhibition of BTK enzymatic activity. BTK is a signaling molecule of the B cell antigen receptor (BCR) and cytokine receptor pathways. In B cells, BTK signaling results in activation of pathways necessary for B-cell proliferation, trafficking, chemotaxis, an adhesion. In nonclinical studies, acalabrutinib inhibited BTK mediated activation of downstream signaling proteins CD86 and CD69 and inhibited malignant B-cell proliferation and survival. Molecular weight: 465.52 Formula: C26H23N7O2 CLOGP: 2.05 LIPINSKI: 0 HAC: 9 HDO: 2 TPSA: 118.51 ALOGS: -4.63 ROTB: 5 Status: ONP Legend: OFP - off patent OFM - off market ONP - on patent

Molecule

Description

Molfile Inchi Smiles

Synonyms:

acalabrutinib
ACP-196
calquence

Acalabrutinib is a small-molecule inhibitor of BTK. Acalabrutinib and its active metabolite, ACP-5862, form a covalent bond with a cysteine residue in the BTK active site, leading to inhibition of BTK enzymatic activity. BTK is a signaling molecule of the B cell antigen receptor (BCR) and cytokine receptor pathways. In B cells, BTK signaling results in activation of pathways necessary for B-cell proliferation, trafficking, chemotaxis, an adhesion. In nonclinical studies, acalabrutinib inhibited BTK mediated activation of downstream signaling proteins CD86 and CD69 and inhibited malignant B-cell proliferation and survival.

Molecular weight: 465.52
Formula: C26H23N7O2
CLOGP: 2.05
LIPINSKI: 0
HAC: 9
HDO: 2
TPSA: 118.51
ALOGS: -4.63
ROTB: 5

Status: ONP

Legend:
OFP - off patent
OFM - off market
ONP - on patent

Drug dosage:

Dose	Unit	Route
0.20	g	O

ADMET properties:

None

Approvals:

Date	Agency	Company	Orphan
Oct. 31, 2017	FDA	ACERTA PHARMA BV
Jan. 22, 2021	PMDA	ASTRAZENECA K.K.

FDA Adverse Event Reporting System (Female)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Death	107.05	37.70	50	326	325329	50279419
Malignant neoplasm progression	43.61	37.70	17	359	68107	50536641

FDA Adverse Event Reporting System (Male)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Death	267.16	33.74	140	627	341944	29231816
COVID-19	58.50	33.74	25	742	35989	29537771
Malignant neoplasm progression	36.38	33.74	23	744	73836	29499924

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Death	217.53	33.98	109	711	482596	64015316
COVID-19	41.56	33.98	19	801	65121	64432791

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

Source	Code	Description
ATC	L01EL02	ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS ANTINEOPLASTIC AGENTS PROTEIN KINASE INHIBITORS Bruton's tyrosine kinase (BTK) inhibitors
MeSH PA	D000970	Antineoplastic Agents
FDA MoA	N0000020001	Tyrosine Kinase Inhibitors
FDA EPC	N0000175605	Kinase Inhibitor
CHEBI has role	CHEBI:35610	antineoplastic agents
CHEBI has role	CHEBI:68495	Type I cell-death inducers
CHEBI has role	CHEBI:76617	BTK inhibitor

Drug Use | Suggest Off label Use Form| |View source of the data|

Disease	Relation	SNOMED_ID	DOID
Chronic lymphocyticleukemia/small lymphocytic lymphoma	indication	92814006
Mantle cell lymphoma	indication	443487006

🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation level	Dissociation constant	Type (acidic/basic)
pKa1	11.34	acidic
pKa2	3.25	Basic
pKa3	2.49	Basic
pKa4	1.5	Basic

Orange Book patent data (new drug applications)

Formulation strength	Trade name	Applicant	Application number	Approval date	Type	Dose form	Route	Patent number	Patent expiration date	Patent use
100MG	CALQUENCE	ASTRAZENECA	N210259	Oct. 31, 2017	RX	CAPSULE	ORAL	10239883	July 11, 2032	TREATMENT OF ADULT PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA
100MG	CALQUENCE	ASTRAZENECA	N210259	Oct. 31, 2017	RX	CAPSULE	ORAL	10239883	July 11, 2032	TREATMENT OF ADULT PATIENTS WITH PREVIOUSLY UNTREATED CHRONIC LYMPHOCYTIC LEUKEMIA IN COMBINATION WITH OBINUTUZUMAB
100MG	CALQUENCE	ASTRAZENECA	N210259	Oct. 31, 2017	RX	CAPSULE	ORAL	9758524	July 11, 2032	TREATMENT OF ADULT PATIENTS WITH MANTLE CELL LYMPHOMA WHO HAVE RECEIVED AT LEAST ONE PRIOR THERAPY
100MG	CALQUENCE	ASTRAZENECA	N210259	Oct. 31, 2017	RX	CAPSULE	ORAL	10272083	Jan. 21, 2035	TREATMENT OF ADULT PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA BY ADMINISTERING 100MG OF ACALABRUTINIB TWICE DAILY
100MG	CALQUENCE	ASTRAZENECA	N210259	Oct. 31, 2017	RX	CAPSULE	ORAL	10272083	Jan. 21, 2035	TREATMENT OF ADULT PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA OR SMALL LYMPHOCYTIC LEUKEMIA BY ADMINISTERING 100 MG OF ACALABRUTINIB TWICE DAILY
100MG	CALQUENCE	ASTRAZENECA	N210259	Oct. 31, 2017	RX	CAPSULE	ORAL	10272083	Jan. 21, 2035	TREATMENT OF ADULT PATIENTS WITH MANTLE CELL LYMPHOMA WHO HAVE RECEIVED AT LEAST ONE PRIOR THERAPY BY ADMINISTERING 100 MG OF ACALABRUTINIB TWICE DAILY
100MG	CALQUENCE	ASTRAZENECA	N210259	Oct. 31, 2017	RX	CAPSULE	ORAL	10272083	Jan. 21, 2035	TREATMENT OF ADULT PATIENTS WITH PREVIOUSLY UNTREATED CHRONIC LYMPHOCYTIC LEUKEMIA BY ADMINISTERING 100 MG OF ACALABRUTINIB TWICE DAILY IN COMBINATION WITH OBINUTUZUMAB
100MG	CALQUENCE	ASTRAZENECA	N210259	Oct. 31, 2017	RX	CAPSULE	ORAL	10272083	Jan. 21, 2035	TREATMENT OF ADULT PATIENTS WITH PREVIOUSLY UNTREATED CHRONIC LYMPHOCYTIC LEUKEMIA OR SMALL LYMPHOCYTIC LEUKEMIA IN COMBINATION WITH OBINUTUZUMAB BY ADMINISTERING 100 MG OF ACALABRUTINIB TWICE DAILY
100MG	CALQUENCE	ASTRAZENECA	N210259	Oct. 31, 2017	RX	CAPSULE	ORAL	10272083	Jan. 21, 2035	TREATMENT OF ADULT PATIENTS WITH PREVIOUSLY UNTREATED SMALL LYMPHOCYTIC LEUKEMIA BY ADMINISTERING 100 MG OF ACALABRUTINIB TWICE DAILY IN COMBINATION WITH OBINUTUZUMAB
100MG	CALQUENCE	ASTRAZENECA	N210259	Oct. 31, 2017	RX	CAPSULE	ORAL	10272083	Jan. 21, 2035	TREATMENT OF ADULT PATIENTS WITH SMALL LYMPHOCYTIC LEUKEMIA BY ADMINISTERING 100MG OF ACALABRUTINIB TWICE DAILY
100MG	CALQUENCE	ASTRAZENECA	N210259	Oct. 31, 2017	RX	CAPSULE	ORAL	10167291	July 1, 2036	TREATMENT OF ADULT PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA
100MG	CALQUENCE	ASTRAZENECA	N210259	Oct. 31, 2017	RX	CAPSULE	ORAL	10167291	July 1, 2036	TREATMENT OF ADULT PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA OR SMALL LYMPHOCYTIC LEUKEMIA
100MG	CALQUENCE	ASTRAZENECA	N210259	Oct. 31, 2017	RX	CAPSULE	ORAL	10167291	July 1, 2036	TREATMENT OF ADULT PATIENTS WITH MANTLE CELL LYMPHOMA WHO HAVE RECEIVED AT LEAST ONE PRIOR THERAPY
100MG	CALQUENCE	ASTRAZENECA	N210259	Oct. 31, 2017	RX	CAPSULE	ORAL	10167291	July 1, 2036	TREATMENT OF ADULT PATIENTS WITH PREVIOUSLY UNTREATED CHRONIC LYMPHOCYTIC LEUKEMIA IN COMBINATION WITH OBINUTUZUMAB
100MG	CALQUENCE	ASTRAZENECA	N210259	Oct. 31, 2017	RX	CAPSULE	ORAL	10167291	July 1, 2036	TREATMENT OF ADULT PATIENTS WITH PREVIOUSLY UNTREATED CHRONIC LYMPHOCYTIC LEUKEMIA OR SMALL LYMPHOCYTIC LEUKEMIA IN COMBINATION WITH OBINUTUZUMAB
100MG	CALQUENCE	ASTRAZENECA	N210259	Oct. 31, 2017	RX	CAPSULE	ORAL	10167291	July 1, 2036	TREATMENT OF ADULT PATIENTS WITH PREVIOUSLY UNTREATED SMALL LYMPHOCYTIC LEUKEMIA IN COMBINATION WITH OBINUTUZUMAB
100MG	CALQUENCE	ASTRAZENECA	N210259	Oct. 31, 2017	RX	CAPSULE	ORAL	10167291	July 1, 2036	TREATMENT OF ADULT PATIENTS WITH SMALL LYMPHOCYTIC LEUKEMIA
100MG	CALQUENCE	ASTRAZENECA	N210259	Oct. 31, 2017	RX	CAPSULE	ORAL	9796721	July 1, 2036	TREATMENT OF ADULT PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA
100MG	CALQUENCE	ASTRAZENECA	N210259	Oct. 31, 2017	RX	CAPSULE	ORAL	9796721	July 1, 2036	TREATMENT OF ADULT PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA OR SMALL LYMPHOCYTIC LEUKEMIA
100MG	CALQUENCE	ASTRAZENECA	N210259	Oct. 31, 2017	RX	CAPSULE	ORAL	9796721	July 1, 2036	TREATMENT OF ADULT PATIENTS WITH MANTLE CELL LYMPHOMA WHO HAVE RECEIVED AT LEAST ONE PRIOR THERAPY
100MG	CALQUENCE	ASTRAZENECA	N210259	Oct. 31, 2017	RX	CAPSULE	ORAL	9796721	July 1, 2036	TREATMENT OF ADULT PATIENTS WITH PREVIOUSLY UNTREATED CHRONIC LYMPHOCYTIC LEUKEMIA IN COMBINATION WITH OBINUTUZUMAB
100MG	CALQUENCE	ASTRAZENECA	N210259	Oct. 31, 2017	RX	CAPSULE	ORAL	9796721	July 1, 2036	TREATMENT OF ADULT PATIENTS WITH PREVIOUSLY UNTREATED CHRONIC LYMPHOCYTIC LEUKEMIA OR SMALL LYMPHOCYTIC LEUKEMIA IN COMBINATION WITH OBINUTUZUMAB
100MG	CALQUENCE	ASTRAZENECA	N210259	Oct. 31, 2017	RX	CAPSULE	ORAL	9796721	July 1, 2036	TREATMENT OF ADULT PATIENTS WITH PREVIOUSLY UNTREATED SMALL LYMPHOCYTIC LEUKEMIA IN COMBINATION WITH OBINUTUZUMAB
100MG	CALQUENCE	ASTRAZENECA	N210259	Oct. 31, 2017	RX	CAPSULE	ORAL	9796721	July 1, 2036	TREATMENT OF ADULT PATIENTS WITH SMALL LYMPHOCYTIC LEUKEMIA

Orange Book exclusivity data (new drug applications)

Formulation strength	Trade name	Applicant	Application number	Approval date	Type	Dose form	Route	Exclusivity date	Description
100MG	CALQUENCE	ASTRAZENECA	N210259	Oct. 31, 2017	RX	CAPSULE	ORAL	Oct. 31, 2022	NEW CHEMICAL ENTITY
100MG	CALQUENCE	ASTRAZENECA	N210259	Oct. 31, 2017	RX	CAPSULE	ORAL	Nov. 21, 2022	TREATMENT OF ADULT PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) OR SMALL LYMPHOCYTIC LYMPHOMA (SLL)
100MG	CALQUENCE	ASTRAZENECA	N210259	Oct. 31, 2017	RX	CAPSULE	ORAL	Oct. 31, 2024	TREATMENT OF ADULT PATIENTS WITH MANTLE CELL LYMPHOMA (MCL) WHO HAVE RECEIVED AT LEAST ONE PRIOR THERAPY
100MG	CALQUENCE	ASTRAZENECA	N210259	Oct. 31, 2017	RX	CAPSULE	ORAL	Nov. 21, 2026	INDICATED FOR THE TREATMENT OF ADULT PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) OR SMALL LYMPHOCYTIC LYMPHOMA (SLL)

Bioactivity Summary:

Target	Class	Pharos	UniProt	Action	Type	Activity value (-log[M])	Bioact source	MoA source
Tyrosine-protein kinase BTK	Kinase	Q06187	BTK_HUMAN	INHIBITOR	IC50	8.29	SCIENTIFIC LITERATURE	DRUG LABEL
Tyrosine-protein kinase Lyn	Kinase	P07948	LYN_HUMAN	INHIBITOR	EC50	6	IUPHAR
Platelet glycoprotein VI	Unclassified	Q9HCN6	GPVI_HUMAN		IC50	5.92	CHEMBL
Receptor tyrosine-protein kinase erbB-4	Kinase	Q15303	ERBB4_HUMAN	INHIBITOR	IC50	7.80	SCIENTIFIC LITERATURE
Receptor tyrosine-protein kinase erbB-2	Kinase	P04626	ERBB2_HUMAN		Kd	8.13	CHEMBL
Tyrosine-protein kinase Tec	Kinase	P42680	TEC_HUMAN	INHIBITOR	IC50	7.03	SCIENTIFIC LITERATURE
Tyrosine-protein kinase TXK	Kinase	P42681	TXK_HUMAN	INHIBITOR	IC50	6.43	SCIENTIFIC LITERATURE
Cytoplasmic tyrosine-protein kinase BMX	Kinase	P51813	BMX_HUMAN	INHIBITOR	IC50	7.34	SCIENTIFIC LITERATURE

External reference:

ID	Source
I42748ELQW	UNII
C4078312	UMLSCUI
CHEBI:167707	CHEBI
CHEMBL3707348	ChEMBL_ID
71226662	PUBCHEM_CID
DB11703	DRUGBANK_ID
CHEMBL4594293	ChEMBL_ID
D10893	KEGG_DRUG
8912	IUPHAR_LIGAND_ID
1986808	RXNORM
263870	MMSL
33203	MMSL
d08672	MMSL
763037006	SNOMEDCT_US
763502000	SNOMEDCT_US
4037065	VANDF
017393	NDDF
C000604908	MESH_SUPPLEMENTAL_RECORD_UI
10150	INN_ID

Pharmaceutical products:

Product	Category	Ingredients	NDC	Form	Quantity	Route	Marketing	Label
CALQUENCE	HUMAN PRESCRIPTION DRUG LABEL	1	0310-0512	CAPSULE, GELATIN COATED	100 mg	ORAL	NDA	27 sections
CALQUENCE	HUMAN PRESCRIPTION DRUG LABEL	1	0310-0512	CAPSULE, GELATIN COATED	100 mg	ORAL	NDA	27 sections